A new study aims to help healthcare providers more effectively implement Apretude, a medication used for HIV prevention.

Whitman-Walker Health highlights the importance of PrEP in HIV prevention and encourages collective action to increase access ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Discover how the WHO's new guidelines on lenacapavir could revolutionise HIV prevention, offering a long-acting alternative ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

The World Health Organization (WHO) is recommending a twice-yearly injection of lenacapavir for prevention of HIV, according ...

Kenya is set to introduce a revolutionary injectable HIV prevention drug, Lenacapavir, becoming one of nine African nations ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...